- Previous Close
52.65 - Open
51.50 - Bid 47.40 x --
- Ask 49.92 x --
- Day's Range
47.18 - 52.20 - 52 Week Range
44.28 - 107.90 - Volume
67,872 - Avg. Volume
29,491 - Market Cap (intraday)
4.635B - Beta (5Y Monthly) 0.90
- PE Ratio (TTM)
14.21 - EPS (TTM)
3.42 - Earnings Date May 14, 2025
- Forward Dividend & Yield 1.10 (1.42%)
- Ex-Dividend Date Mar 23, 2023
- 1y Target Est
--
Carl Zeiss Meditec AG operates as a medical technology company in Germany, rest of Europe, the United States, Asia, and internationally. It operates in two segments, Ophthalmic Devices and Microsurgery. The Ophthalmic Devices segment offers offers products and solutions for the diagnosis and treatment of chronic eye diseases; and systems and consumables for refractive surgery. This segment also provides slit lamps, refractometers, tonometers, optical coherence tomography devices, and fundus cameras used for the examination of the retina in hospitals and practices; and equipment for functional diagnostics. In addition, this segment offers surgical microscopes, biometers, and phacoemulsification or vitrectomy devices; and intraocular lenses for cataract patients. The Microsurgery segment offers visualization solutions for invasive surgical treatments; and solutions in the area of ear, nose and throat, plastic and reconstructive, neuro, dental, and spinal surgeries. It serves physicians in various fields and hospitals. The company was founded in 1846 and is headquartered in Jena, Germany. Carl Zeiss Meditec AG is a subsidiary of Carl Zeiss AG.
www.zeiss.de/meditec-ag/home.html4,224
Full Time Employees
September 30
Fiscal Year Ends
Sector
Medical Instruments & Supplies
Industry
Recent News: 0DHC.IL
View MorePerformance Overview: 0DHC.IL
Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is DAX P (^GDAXI) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 0DHC.IL
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 0DHC.IL
View MoreValuation Measures
Market Cap
4.27B
Enterprise Value
4.40B
Trailing P/E
24.18
Forward P/E
25.06
PEG Ratio (5yr expected)
1.20
Price/Sales (ttm)
2.09
Price/Book (mrq)
2.08
Enterprise Value/Revenue
2.13
Enterprise Value/EBITDA
10.91
Financial Highlights
Profitability and Income Statement
Profit Margin
14.81%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
2.08B
Net Income Avi to Common (ttm)
307.91M
Diluted EPS (ttm)
3.42
Balance Sheet and Cash Flow
Total Cash (mrq)
12.36M
Total Debt/Equity (mrq)
7.92%
Levered Free Cash Flow (ttm)
--